# QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

> **NCT06404736** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 73 (estimated)

## Conditions studied

- Early Breast Cancer
- Neoadjuvant Therapy
- TNBC, Triple Negative Breast Cancer

## Interventions

- **DRUG:** Bispecific antibody (bsAb) targeting PD-1 and CLTA-4
- **DRUG:** Albumin-bound paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06404736
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-07
- **Primary completion:** 2025-11-07
- **Final completion:** 2030-11-07
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06404736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06404736, "QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06404736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*